Navigation Links
New research could pave the way to safer treatments for arthritis
Date:7/4/2013

The increased risk of heart attack or stroke associated with many arthritis drugs may be avoidable, according to a new international study co-authored by researchers at Imperial College London.

Drugs such as Vioxx, diclofenac, ibuprofen and Celebrex operate by blocking an enzyme known as COX-2, whose presence in blood vessels has up until now been held responsible for these side effects. New research carried out on mice has revealed that COX-2 is largely absent from the major blood vessels and instead found in the brain, gut, and kidney as well as the thymus gland in the chest.

Now that researchers know where in the body the drug is acting, they can begin to develop safer, more targeted drugs for patients with arthritis as well as cancer.

Arthritis drugs have long been associated with potentially fatal cardiovascular side-effects in patients. Health concerns led to the anti-inflammatory Vioxx being withdrawn from the market in 2004, and this week medical regulators have advised some patients to stop using the painkiller diclofenac.

Researchers have always believed that COX-2 was found in the blood vessels where it was central to preventing the formation of clots. This meant that any drug that inhibited the enzyme was thought to lead to an increased risk of clotting.

The new study, published today in the journal PLOS ONE, reveals that COX-2 is largely absent from the major blood vessels. Instead COX-2 appears to be present in the brain, kidney, thymus and gut, where it may well be affecting the cardiovascular health.

Lead author, Professor Jane Mitchell of Imperial's Faculty of Medicine said: "Now we know the true sites of COX-2, we can begin to develop new ideas that will lead to better drugs for arthritis and cancer with fewer side effects."

The new research suggests future development of COX-2 inhibitors that carry reduced risk of stroke or heart attack may be possible. Professor Mitchell added: "This study does not provide all the answers, but once we understand exactly how COX-2 affects the cardiovascular system we will be in a position to design new therapies. This will not be easy but all the tools are available and we could be looking at new leads within five to ten years."

In order to accurately measure concentrations of COX-2 within the body, the researchers used mice whose COX-2 gene had been replaced with a gene called luciferase, which gives fireflies their distinctive glow. This allowed researchers to create detailed images of the distribution of COX-2 throughout the body.

Professor Anna Nicolaou, a co-author, now at the University of Manchester, said: "This study is the first to use such sophisticated techniques to determine the locations of COX-2 within the body. The use of mass spectrometry and genetically modified mice in this way represents a significant advance in the field."

This was echoed by Professor Tim Warner, a co-author from Queen Mary, University of London, who said: "These cutting edge techniques are at last supplying us with the definitive answers we need to understand the side effects of arthritis drugs. This could help improve therapy for many millions of patients worldwide."


'/>"/>

Contact: Gilead Amit
gda07@imperial.ac.uk
Imperial College London
Source:Eurekalert

Related medicine news :

1. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
2. NIH awards $20 million over 5 years to train next generation of global health researchers
3. Researchers develop a new cell and animal model of inflammatory breast cancer
4. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
5. Sexually abused boys at risk for more unsafe sex: UBC research
6. Researchers Find Gene Mutations That May Be a Key to Autism
7. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
8. Researchers find evidence of banned antibiotics in poultry products
9. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
10. Scientific session and new research highlights
11. NJ stroke researchers report advances in spatial neglect research at AAN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... NY (PRWEB) , ... January 20, 2017 , ... ... VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been produced ... with optimal conditions to perform during your workout. , After a successful launch ...
(Date:1/20/2017)... ... ... fine examination of how God handles sin, including how to let go of lingering guilt ... over ten long years has been waiting to release this powerful insight about forgiveness that ... serving the Lord for over twenty years, and he has been preaching and teaching the ...
(Date:1/20/2017)... ... 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection ... is the creation of published author, Gene Gaapf, a retired truck driver, and a ... have been writing since high school and have many different titles,” Gaapf mentions about ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... an On-demand E-learning system for Clinical and Regulatory education for Physicians, Physician ... on Aerolib`s successful education methodology of Disease Specific Documentation Improvement. , The ...
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO and ... name of their drug rehab center in Delray Beach, Florida has been changed from ... only stars such as Philip Seymour Hoffman and Chris Farley are dying from heroin ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... BOSTON , Jan. 19, 2017  Stealth BioTherapeutics ... therapeutics to treat mitochondrial dysfunction, today announced new additions ... , M.D., as Chief Medical Officer, and Daniel ... Stealth announced that Jim Carr , Pharm.D. has ... "We are pleased to welcome Doug and Daniel ...
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... blood analysis instruments and consumables for the medical and ... discuss its financial results for the third quarter fiscal ... be at 4:15 p.m. ET on Thursday, January 26, ... third quarter fiscal year 2017 after the market closes ...
(Date:1/19/2017)... , January 19, 2017 ... announced that the U.S. Food and Drug Administration (FDA) ... a New Drug Application (NDA) for SHP465, a long-acting, ... as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). ... or around June 20, 2017, the designated Prescription Drug ...
Breaking Medicine Technology: